week 3 tirzepatide Side Effects Timeline: by Week and Month by Month for Mounjaro® and Zepbound® My Tirzepatide Week 3: Lost

DATA GRAPHICS | Product Development Retatrutide data strengthen Lillys hand in high-BMI obesity Phase III data put weight loss above CagriSemas benchmark, with tolerability that may be good enough to preserve a commercial edge May 21, 2026 7:09 PM UTC Lilly again has the frontrunner in the weight loss Olympics: its triple agonist retatrutide showed greater Phase III obesity efficacy than Novo Nordisks dual-acting CagriSema, with a tolerability profile that does not appear markedly worse

Once you get the hang of it, self-administering semaglutide at home is easy and can fit smoothly into your schedule

In fact, such a design incorporates substantial uncertainty if background therapy, population risk, or adherence differs significantly from historical trials, especially in view of the rapidly changing scenario of T2D management with a treat-to-benefit approach

If you want a deeper look at the mechanism behind these treatments, our GLP-1 weight loss explainer is a helpful companion read

Fatty acid oxidation increases

This month is about adaptation, not results